uveitis. Invest Ophthalmol Vis Sci 49: 3058-64 Fossiez F, Djossou O, Chomarat P et al. (1996) T cell IL-17 induces stromal cells to produce proinflamatory and hematopoietic cytokines. TO THE EDITOR I read with interest the study by Harder et al. (2010) , as they confirmed the previous finding that the human b defensin-2 (hBD-2) level in atopic dermatitis (AD) lesions is lower than that in psoriatic lesions, but higher than healthy skin (Ong et al., 2002) . Based on the observation that psoriasis patients rarely suffer from skin infections (Henseler and Christophers, 1995) , Harder et al. (1997) made their seminal discovery of hBD-2 in psoriatic lesions. This antimicrobial peptide (AMP) has since been proven to be the strongest and most psoriasis-specific protein (de Jongh et al., 2005; Gambichler et al., 2008) . In addition, it has been shown to have immunomodulatory effects on innate and adaptive immunity (Yang et al., 1999) . Although hBD-2 has weak direct antimicrobial activity against Staphylococcus aureus (Harder et al., 1997), the amount of hBD-2 present in psoriatic lesions significantly exceeds the amount required for both antimicrobial effects (2.5-25 mM) and immunomodulation (2.5-250 nM) (Jansen et al., 2009) . On the other hand, the amount of hBD-2 present in AD lesions, although higher than that in healthy skin, has not been proven to exceed these ranges. Furthermore, correlation between hBD-2 level and clinical infection in AD has not been studied. However, the findings of Harder et al.
Abbreviations: AD, atopic dermatitis; AMP, antimicrobial peptide; CCR6, chemokine receptor; hBD-2, human b defensin-2 (2010) do raise the interesting question as to how the presence of other AMPs, which apparently have good direct anti-S. aureus activity, is incapable of controlling skin infections in AD.
Although recent studies have focused on the regulation of AMPs by adaptive immunity, it is not clear how the relatively high expression of IL-22, a key cytokine of adaptive immunity that regulates AMPs, does not appear to upregulate hBD-2 level in AD (Wolk et al., 2004) . hBD-2 has led the way in studies of AMPs' effects on adaptive immunity (Yang et al., 1999) . It binds and attracts cells expressing the chemokine receptor, CCR6 (Röhrl et al., 2010) . A significant proportion of CCR6-expressing T helper cells also produce IFN-g, IL-17, and/or IL-22 (Ong and Leung, 2002; Duhen et al., 2009) . The increased and decreased expression of IFN-g/IL-17 in psoriatic and AD lesions, respectively (Lowes et al., 2008) (Guttman-Yassky et al., 2008) , are not inconsistent with the ability of hBD-2 to drive adaptive immunity against skin infections. However, this hypothesis needs to be verified further. As a proportion of AD patients are not affected by skin infections (David and Cambridge, 1986) , it may be of interest to evaluate whether there is any correlation between hBD-2 level and clinical infection in AD. Further studies on the exact role of hBD-2 in adaptive immunity are needed before it is dismissed in relation to the skin infections in AD.
